SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001193125-16-772374
Filing Date
2016-11-18
Accepted
2016-11-18 16:46:02
Documents
1
Group Members
EDWIN M. KANIA, JR.FLAGSHIP VENTURES 2007 GENERAL PARTNER LLCFLAGSHIP VENTURES FUND IV GENERAL PARTNER LLCFLAGSHIP VENTURES FUND IV, L.P.FLAGSHIP VENTURES FUND IV-RX, L.P.NOUBAR B. AFEYAN, PH.D.

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO.3 TO SCHEDULE 13D d284287dsc13da.htm SC 13D/A 118132
  Complete submission text file 0001193125-16-772374.txt   119938
Mailing Address 215 FIRST STREET SUITE 400 CAMBRIDGE MA 02142
Business Address 215 FIRST STREET SUITE 400 CAMBRIDGE MA 02142 617-871-9911
Eleven Biotherapeutics, Inc. (Subject) CIK: 0001485003 (see all company filings)

IRS No.: 252025616 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-87951 | Film No.: 162008292
SIC: 2834 Pharmaceutical Preparations

Mailing Address 55 CAMBRIDGE PARKWAY, 8TH FLOOR CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY, 8TH FLOOR CAMBRIDGE MA 02142 617-868-1888
Flagship Ventures Fund 2007, L.P. (Filed by) CIK: 0001508052 (see all company filings)

IRS No.: 260552049 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A